Traphaco Past Earnings Performance
Past criteria checks 3/6
Traphaco has been growing earnings at an average annual rate of 11.6%, while the Pharmaceuticals industry saw earnings growing at 11.9% annually. Revenues have been growing at an average rate of 7.3% per year. Traphaco's return on equity is 18.2%, and it has net margins of 9.4%.
Key information
11.6%
Earnings growth rate
11.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 13.0% |
| Revenue growth rate | 7.3% |
| Return on equity | 18.2% |
| Net Margin | 9.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Traphaco makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 2,227,617 | 210,488 | 897,855 | 0 |
| 31 Dec 23 | 2,299,235 | 229,440 | 911,561 | 0 |
| 30 Sep 23 | 2,292,623 | 217,023 | 954,042 | 0 |
| 30 Jun 23 | 2,320,994 | 223,517 | 977,664 | 0 |
| 31 Mar 23 | 2,394,035 | 225,969 | 1,023,094 | 0 |
| 31 Dec 22 | 2,398,918 | 235,185 | 992,618 | 0 |
| 30 Sep 22 | 2,389,723 | 253,883 | 945,902 | 0 |
| 30 Jun 22 | 2,353,551 | 246,853 | 905,619 | 0 |
| 31 Mar 22 | 2,313,116 | 237,067 | 845,963 | 0 |
| 31 Dec 21 | 2,160,840 | 209,901 | 820,855 | 0 |
| 30 Sep 21 | 2,191,557 | 204,915 | 854,541 | 0 |
| 30 Jun 21 | 2,082,080 | 188,623 | 831,386 | 0 |
| 31 Mar 21 | 1,988,241 | 173,516 | 794,585 | 0 |
| 31 Dec 20 | 1,908,870 | 172,611 | 762,342 | 0 |
| 30 Sep 20 | 1,846,090 | 176,937 | 745,535 | 0 |
| 30 Jun 20 | 1,762,663 | 159,869 | 714,885 | 0 |
| 31 Mar 20 | 1,736,640 | 139,298 | 758,712 | 0 |
| 31 Dec 19 | 1,710,439 | 134,818 | 712,589 | 0 |
| 30 Sep 19 | 1,703,913 | 139,347 | 676,467 | 0 |
| 30 Jun 19 | 1,795,932 | 142,720 | 711,553 | 0 |
| 31 Mar 19 | 1,798,990 | 139,146 | 693,029 | 0 |
| 31 Dec 18 | 1,798,350 | 137,713 | 707,981 | 0 |
| 30 Sep 18 | 1,825,079 | 148,223 | 732,272 | 0 |
| 30 Jun 18 | 1,809,549 | 169,668 | 708,477 | 0 |
| 31 Mar 18 | 1,833,899 | 207,822 | 691,608 | 0 |
| 31 Dec 17 | 1,870,442 | 217,140 | 717,598 | 0 |
| 30 Sep 17 | 1,806,911 | 189,374 | 671,974 | 0 |
| 30 Jun 17 | 1,838,707 | 186,362 | 668,608 | 0 |
| 31 Mar 17 | 1,890,096 | 180,072 | 655,413 | 0 |
| 31 Dec 16 | 1,998,334 | 189,062 | 646,257 | 0 |
| 30 Sep 16 | 2,034,951 | 205,819 | 616,780 | 0 |
| 30 Jun 16 | 2,029,519 | 198,536 | 604,429 | 0 |
| 31 Mar 16 | 2,023,193 | 181,332 | 599,298 | 0 |
| 31 Dec 15 | 1,974,002 | 163,210 | 591,399 | 0 |
| 30 Sep 15 | 1,958,262 | 148,334 | 575,780 | 0 |
| 30 Jun 15 | 1,893,579 | 145,606 | 552,900 | 0 |
| 31 Mar 15 | 1,821,132 | 145,739 | 517,685 | 0 |
| 31 Dec 14 | 1,650,722 | 132,427 | 459,967 | 0 |
| 30 Sep 14 | 1,538,937 | 125,018 | 456,232 | 0 |
| 30 Jun 14 | 1,552,664 | 125,497 | 455,961 | 0 |
| 31 Mar 14 | 1,537,105 | 134,616 | 446,719 | 0 |
| 31 Dec 13 | 1,682,364 | 149,422 | 477,951 | 0 |
| 30 Sep 13 | 1,683,232 | 152,919 | 463,605 | 0 |
| 30 Jun 13 | 1,607,352 | 145,784 | 434,752 | 0 |
Quality Earnings: TRA has high quality earnings.
Growing Profit Margin: TRA's current net profit margins (9.4%) are higher than last year (9.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRA's earnings have grown by 11.6% per year over the past 5 years.
Accelerating Growth: TRA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: TRA had negative earnings growth (-6.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-5.5%).
Return on Equity
High ROE: TRA's Return on Equity (18.2%) is considered low.